Literature DB >> 6183699

Interferon: pharmacokinetics and toxicity.

G M Scott.   

Abstract

Interferons disappear rapidly from the serum of animals and man, and the kidney may be the major site of interferon destruction. The relevance of serum levels of interferons to their therapeutic activity has not been clearly established, particularly as the stimulation of host defence mechanisms by interferons may be important. Relatively low serum levels of antiviral activity are seen after intramuscular injections of fibroblast interferon compared with those after the same dose of leucocyte interferon. Injections of very pure leucocyte and lymphoblastoid interferons from several sources cause fever, headaches, malaise and myalgia associated with a corticosteroid response and probably with inflammatory prostaglandin synthesis. These reactions become less with repeated dosing but very large doses of lymphoblastoid interferon have been shown to cause liver damage and serious metabolic disturbances. Treatment with moderate doses of exogenous interferons may occasionally be associated with the development of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183699     DOI: 10.1098/rstb.1982.0109

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  8 in total

1.  Pharmacokinetics of recombinant interferon alpha-C.

Authors:  O Merimsky; M Rubinstein; D Fischer; A Danon; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Safety evaluation of biotechnology products.

Authors:  G Zbinden
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

3.  [Beta interferon therapy in hairy cell leukemia].

Authors:  P von Wussow; J Dühlmann; T Grethlein; W D Hirschmann; E Hügl; O Koch; W R Martin; H W Pees; W Urbanitz; M Freund
Journal:  Klin Wochenschr       Date:  1987-07-15

4.  Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; D Desprès; J Aman; P Trautman; H Tilg; G Rudolf; H Hüttmann; J Obermeier; M Herold
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

5.  Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.

Authors:  Hussein El-Fishawy; Gamal Saadi; May Hassaballa; Mohamed Hussein; Wahid Doss; Gaafar Ragab; Rashad Barsoum
Journal:  J Adv Res       Date:  2016-03-02       Impact factor: 10.479

Review 6.  Hepatitis C and kidney disease: A narrative review.

Authors:  Rashad S Barsoum; Emad A William; Soha S Khalil
Journal:  J Adv Res       Date:  2016-07-26       Impact factor: 10.479

7.  Tolerance of one-month intranasal interferon.

Authors:  G M Scott; J K Onwubalili; J A Robinson; C Doré; D S Secher; K Cantell
Journal:  J Med Virol       Date:  1985-10       Impact factor: 2.327

8.  Interferons as cytokines regulating leukocyte functions in vivo.

Authors:  J L Virelizier
Journal:  Ann Inst Pasteur Immunol (1985)       Date:  1985 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.